{"entity":{"id":"nct04641247","kind":"trial","name":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study","aka":[],"tldr":"A phase 2 trial of Niraparib in ovarian cancer, run by GlaxoSmithKline, now recruiting.","summary":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study is a phase 2 interventional study registered as NCT04641247 by GlaxoSmithKline, with 37 participants planned, started 2021-04-16 and due to reach its primary completion in 2026-12-28. Interventions recorded: Niraparib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04641247","url":"https://clinicaltrials.gov/study/NCT04641247"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["niraparib"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04641247","phase":"2","setting":"An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib","sponsor":"GlaxoSmithKline","participation":[{"nct":"NCT04641247","source":"https://clinicaltrials.gov/study/NCT04641247","fetchedAt":"2026-10-07T16:53:24.647Z","studySha256":"e09842cbd25be8026bba452db68bd59370943ba812d14a2f8b3c00b87e1da55b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-24","leadSponsor":"GlaxoSmithKline","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":37,"enrolmentType":"ESTIMATED","siteCount":25,"recruitingSiteCount":18,"countries":["Austria","Canada","Denmark","France","Israel","Italy","Spain","United States"]}],"started":"2021-04-16","startedType":"actual","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04641247/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}